格隆汇3月19日丨李氏大药厂(00950.HK)发布公告，集团预期截至2024年12月31日止年度将录得股东应占未经审核纯利介乎8300万港元至1.06亿港元，而2023年度则录得约1700万港元。
公告表示，尽管已计提南沙的土地使用权拨备及若干研究及开发项目的减值亏损，惟本集团的年度业绩大幅改善，主要受以下因素推动，其中包括(i)获纳入最新版《国家基本医疗保险、工伤保险和生育保险药品目录》的产品（例如曲前列尼尔注射液《芮旎尔®》、《芮舒延®》及《曲特恪®》）连同药品集采计划的选定产品（例如那曲肝素钙注射液《立腾菁®》）的销售增长于回顾年度内显著改善销售收益；(ii)藉优化研究及开发组合使研究及开发费用减少；及(iii)集团优化管理的举措所节省的成本。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.